Single Pass has developed a patented device to improve the safety of biospy procedures. The management team has over 100 years of experience developing medical devices and has been part of several previous start-up exits. The product has received the CE Mark and is generating revenue in Europe through a group of independent distribution companies.. The company expects to have enough market traction to become an acquisition candidate in 2024